Download Citation
Article Source:
Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies
Olive JF,
Qin Y,
DeCristo MJ,
Laszewski T,
Greathouse F,
et al.
(2018)
Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies.
PLOS ONE 13(6): e0198790.
https://doi.org/10.1371/journal.pone.0198790